We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+7.08%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$809M
AUM Growth
+$404M
Cap. Flow
+$13B
Cap. Flow %
1,601.81%
Top 10 Hldgs %
38.43%
Holding
159
New
60
Increased
32
Reduced
34
Closed
31

Top Buys

Rank Stock Value
1
ISRL
Isramco Inc
ISRL
+$12.6B
2
AGN
Allergan plc
AGN
+$27.3M
3
ABBV icon
AbbVie
ABBV
+$22.4M
4
SHPG
Shire pic
SHPG
+$19.6M
5
PFE icon
Pfizer
PFE
+$18.3M

Top Sells

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$12.7M
2
GSK icon
GSK
GSK
+$9.95M
3
BIIB icon
Biogen
BIIB
+$6.94M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$5.6M
5
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$5.12M

Sector Composition

Rank Sector Weight
1 Healthcare 57.07%
2 Technology 4.45%
3 Energy 3.1%
4 Industrials 2.68%
5 Materials 1.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVS icon
1
Novartis
NVS
$297B
$45.2M 5.58%
534,476
-60,464
-10% -$4.89M
XNTK icon
2
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2.06B
$39.4M 4.87%
+400,000
New +$19.5M
PFE icon
3
Pfizer
PFE
$143B
$37.7M 4.65%
1,342,810
+652,866
+95% +$18.3M
TEVA icon
4
Teva Pharmaceuticals
TEVA
$40.8B
$34.8M 4.3%
647,438
+202,938
+46% +$10.8M
XLV icon
5
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$41.9B
$31M 3.83%
+485,500
New +$30.4M
AGN
6
DELISTED
Allergan plc
AGN
$29.5M 3.64%
+122,100
New +$27.3M
MRK icon
7
Merck
MRK
$322B
$24.8M 3.06%
437,571
-13,069
-3% -$734K
ABBV icon
8
AbbVie
ABBV
$443B
$23.3M 2.88%
+403,550
New +$22.4M
AGN
9
DELISTED
Allergan Inc
AGN
$23M 2.84%
128,840
+88,840
+222% +$14.8M
SHPG
10
DELISTED
Shire pic
SHPG
$22.4M 2.77%
259,085
+79,085
+44% +$19.6M
ISRL
11
DELISTED
Isramco Inc
ISRL
$22.1M 2.73%
+103,111,944
New +$12.6B
JNJ icon
12
Johnson & Johnson
JNJ
$618B
$22.1M 2.73%
207,406
-6,194
-3% -$642K
GILD icon
13
CALL
Gilead Sciences
GILD
$162B
$20.7M 2.55%
194,200
+192,200
+9,610% +$18.8M
TEVA icon
14
CALL
Teva Pharmaceuticals
TEVA
$40.8B
$20.2M 2.49%
375,200
+371,990
+11,588% +$19.7M
VRTX icon
15
Vertex Pharmaceuticals
VRTX
$121B
$16.8M 2.08%
+150,000
New +$14.3M
GSK icon
16
CALL
GSK
GSK
$104B
$13.4M 1.65%
233,040
+230,640
+9,610% +$14.1M
BHC icon
17
Bausch Health
BHC
$2.58B
$12.9M 1.6%
+98,550
New +$11.7M
BHC icon
18
CALL
Bausch Health
BHC
$2.58B
$12.8M 1.58%
+97,200
New +$11.6M
MNK
19
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$12.3M 1.51%
+135,940
New +$10.6M
UTHR icon
20
United Therapeutics
UTHR
$25.8B
$11.4M 1.41%
+88,840
New +$9.16M
ICL icon
21
ICL Group
ICL
$6.53B
$9.98M 1.23%
+1,380,000
New +$9.88M
ESLT icon
22
Elbit Systems
ESLT
$37.9B
$8.97M 1.11%
+144,759
New +$8.83M
ORBK
23
DELISTED
Orbotech Ltd
ORBK
$8.9M 1.1%
571,532
+227,930
+66% +$3.63M
BMRN icon
24
BioMarin Pharmaceuticals
BMRN
$11.6B
$8.8M 1.09%
121,970
+1,970
+2% +$129K
AZN icon
25
AstraZeneca
AZN
$263B
$8.57M 1.06%
+120,000
New +$8.78M
1
2 3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2014 Portfolio in Review

As of Q3 2014, Sphera Funds Management held 159 positions worth $809M, up 99% from $406M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Sphera Funds Management deployed $13B of net new capital in Q3 2014, opening 60 new positions and adding to 32 existing holdings. Its largest new stake was Isramco Inc: 103,111,944 shares worth $22.1M.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, down from 74% a quarter earlier, followed by Technology and Energy.

On the sell side, the largest reduction was GSK, an estimated $9.95M trimmed.

  • Sphera Funds Management's largest Q3 2014 buy was Isramco Inc: 103,111,944 shares worth $22.1M.
  • Sphera Funds Management added most to Shire pic in Q3 2014, an estimated $19.6M increase.
  • Sphera Funds Management's biggest Q3 2014 reduction was GSK, cutting an estimated $9.95M.
  • Sphera Funds Management fully exited Sanofi in Q3 2014, selling an estimated $12.7M.
  • Sphera Funds Management's ten largest holdings make up 38% of its $809M portfolio in Q3 2014.
  • Sphera Funds Management opened 60 new positions and closed 31 in Q3 2014.
  • Sphera Funds Management's portfolio value rose 99% quarter-over-quarter to $809M.

Based on Sphera Funds Management's 13F filing for Q3 2014, filed 13 Nov 2014.